Newly approved drugs targeting epidermal growth factor receptor (EGFR) and poly ADP-ribose polymerase 1 (PARP1) improved the clinical outcomes of non-small cell lung cancer and ovarian cancer patients18,19. This evidence concerns the gene PARP1 and non-small cell lung carcinoma.